[1]纪东华,王峰,李城,等.经肝动脉留置导管持续灌注榄香稀治疗存在肝动静脉或肝动脉门脉瘘的肝癌[J].介入放射学杂志,2007,(08):535.
 JI Dong-hua,WANG Feng,LI Cheng,et al.Hepatic cancer with arteovenous or arteroportal leak:hepatic arterial continuous elemene perfusion with retaining catheter[J].journal interventional radiology,2007,(08):535.
点击复制

经肝动脉留置导管持续灌注榄香稀治疗存在肝动静脉或肝动脉门脉瘘的肝癌()

PDF下载中关闭

分享到:

《介入放射学杂志》[ISSN:1008-794X/CN:31-1796/R]

卷:
期数:
2007年08期
页码:
535
栏目:
肿瘤介入
出版日期:
2007-08-15

文章信息/Info

Title:
Hepatic cancer with arteovenous or arteroportal leak:hepatic arterial continuous elemene perfusion with retaining catheter
作者:
纪东华王峰李城
116011大连医科大学附属第一医院介入治疗科
Author(s):
JI Dong-huaWANG FengLI ChengLIU Yong-shengWANG Ning-fangZHAO Li-jun.
Interventional Treatment Department,The First Affiliated Hospital of Dalian Medical University,Dalian116011,China
关键词:
肝动静脉瘘肝动脉门静脉瘘榄香稀持续灌注
分类号:
R735.7
文献标志码:
A
摘要:
目的探讨榄香稀持续灌注治疗存在肝动静脉或肝动脉门脉瘘的肝癌的疗效。方法62例存在肝动静脉或肝动脉门脉瘘的肝癌患者给予榄香稀经肝动脉留置导管持续灌注治疗。术后定期复查ALT、AST、T-BIL、WBC、AFP等指标以评价肝功能及肿瘤变化,同时还行肝脏CT或MRI及经肝动脉造影观察肿瘤体积、数目的变化及瘘口封堵情况。结果35例(56%)患者肝动脉造影显示原有的瘘口基本闭塞,同时AFP的数值亦有所降低;17例(27%)患者肿瘤体积明显缩小(>50%)。12例(19%)患者生存期超过24个月,其余50例(81%)患者生存期为7~15个月。结论经肝动脉留置导管持续灌注榄香稀治疗存在肝动静脉或肝动脉门脉瘘的肝癌是一种既有效封堵瘘口又最大程度灭活肿瘤的治疗方法。

参考文献/References:

[1]Lin CP,Yu HC,Cheng JS,et al.Clinical effects of intra-arterial infusion chemotherapy with cisplatin,mitomycin C,leucovorin and5-flourouracil for unresectable advanced hepatocellular carcinoma[J].J Chin Med Assoc,2004,67:602-610.
[2]Kato H,Nagano H,Ota H,et al.Successful treatment of com-bined intraarterial(5-fluorouracil and adriamycin and cisplatin)infusion chemotherapy for advanced hepatocellular carcinoma with multiple intrahepatic metastases and/or portal vein thrombosis—two case reports[J].Gan To Kagaku,2005,32:1842-1845.
[3]Lai YC,Shih CY,Jeng CM,et al.Hepatic arterial infusion chemo-therapy for hepatocellular carcinoma with portal vein tumor thrombosis[J].World J Gastroenterol,2003,9:2666-2670.
[4]Yamamoto N,Murata K,Fuka H,et al.Macrocytic anemia dur-ing low-dose cisplatin and5-Fluorouracil through implanted infusion port for unresectable hepatobilliary malignancies[J].Anticancer Res,2005,25:1243-1246.
[5]钱军.抗癌新药一榄香烯的药理及临床[J].中国肿瘤临床,1996,23:453.
[6]吴伟忠,刘康达,汤晓雷,等.β-榄香烯诱导的抗肿瘤免疫保护作用机理初探[J].中华肿瘤杂志,1999,21:405-409.
[7]徐学军,周子成,罗元辉,等.β-榄香烯诱导人肝癌细胞株SMMC-7721凋亡的研究[J].第三军医大学学报,1999,4:268.
[8]肖立森,朱为民.榄香稀经肝动脉介入治疗原发性肝癌的临床研究总结[J].中国肿瘤临床,1996,23:757-785.
[9]陈骏,王峰,杨葆华,等.榄香烯联合介入治疗中晚期肝癌92例[J].介入放射学杂志,2002,11:210-212.
[10]刘雪梅.中药榄香烯乳介入治疗肝癌30例报告[J].中国医师杂志,2002,4:329-330.
[11]华阳,李康,李法庆,等.榄香稀乳剂在治疗原发性肝癌介入治疗中的应用[J].中医药学刊,2003,21:393.
[12]梁宇闯,林坚,李卓永,等.经肝动脉插管灌注榄香稀乳剂治疗中晚期肝癌的观察[J].右江民族医学院学报,2004,26:200-201.

相似文献/References:

[1]林宇宁,杨熙章,李惠敏,等.介入栓塞治疗良性肝动脉-门静脉瘘一例[J].介入放射学杂志,2009,(12):957.
 LIN Yuning,YANG Xizhang,LI Huimin,et al.Interventional embolization therapy for benign hepatic arterioportal fistulas:report of one case[J].journal interventional radiology,2009,(08):957.

备注/Memo

备注/Memo:
收稿日期:2006-12-18
更新日期/Last Update: 2007-08-15